Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (ARTEMIDE-Bil01)

July 9, 2026 updated by: AstraZeneca

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment in participants with BTC after resection with curative intent. This study will be conducted in patients with BTC who are at risk of recurrence after resection with curative intent.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
760

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Australia
      • Camperdown, Australia, 2050
        • Research Site
      • Clayton, Australia, 3168
        • Research Site
      • Murdoch, Australia, 6150
        • Research Site
      • Westmead, Australia, 2145
        • Research Site
  • Belgium
      • Brussels, Belgium, 1200
        • Research Site
      • Brussels, Belgium, 1070
        • Research Site
      • Edegem, Belgium, 2650
        • Research Site
      • Leuven, Belgium, 3000
        • Research Site
  • Brazil
      • Natal, Brazil, 59075-740
        • Research Site
      • Porto Alegre, Brazil, 91350-200
        • Research Site
      • Porto Alegre, Brazil, 90035-000
        • Research Site
      • Santa Maria, Brazil, 97015-450
        • Research Site
      • Santo André, Brazil, 09060-870
        • Research Site
      • São Paulo, Brazil, 01246-000
        • Research Site
      • São Paulo, Brazil, 01327-001
        • Research Site
      • Vitória, Brazil, 29043-260
        • Research Site
  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada, VSZ 4E6
        • Research Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Research Site
    • Ontario
      • Kingston, Ontario, Canada, K7L 2V7
        • Research Site
      • London, Ontario, Canada, N6C 2R5
        • Research Site
      • Ottawa, Ontario, Canada, K1H 8L6
        • Research Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Research Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Research Site
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Research Site
      • Québec, Quebec, Canada, G1J 1Z4
        • Research Site
  • China
      • Beijing, China, 100142
        • Research Site
      • Beijing, China, CN-100730
        • Research Site
      • Changchun, China, 130021
        • Research Site
      • Changsha, China, 410013
        • Research Site
      • Chengdu, China, 610000
        • Research Site
      • Chengdu, China, 610072
        • Research Site
      • Deyang, China, 618000
        • Research Site
      • Fuzhou, China, 350005
        • Research Site
      • Guangzhou, China, 510515
        • Research Site
      • Guiyang, China, 550044
        • Research Site
      • Hangzhou, China, 310009
        • Research Site
      • Harbin, China, 150081
        • Research Site
      • Hefei, China, 230001
        • Research Site
      • Hefei, China, 230601
        • Research Site
      • Kunming, China, 650101
        • Research Site
      • Lanzhou, China, 730000
        • Research Site
      • Lishui, China, 323000
        • Research Site
      • Nanchang, China, 330006
        • Research Site
      • Nanjing, China, 2100008
        • Research Site
      • Nanjing, China, 210029
        • Research Site
      • Nanning, China, 530021
        • Research Site
      • Shandong, China
        • Research Site
      • Shanghai, China, 201114
        • Research Site
      • Shenyang, China, 110004
        • Research Site
      • Tianjin, China, 300060
        • Research Site
      • Wuhan, China, 430079
        • Research Site
      • Wuhan, China, 430071
        • Research Site
      • Xi'an, China, 710061
        • Research Site
      • Zhengzhou, China, 450008
        • Research Site
  • Denmark
      • Herlev, Denmark, 2730
        • Research Site
  • France
      • Marseille, France, 13273
        • Research Site
      • Montpellier, France, 34295
        • Research Site
      • Pessac, France, 33604
        • Research Site
      • Rennes, France, 35000
        • Research Site
      • Strasbourg, France, 67033
        • Research Site
      • Toulouse, France, 31059
        • Research Site
      • Villejuif, France, 94800
        • Research Site
  • Germany
      • Berlin, Germany, 13353
        • Research Site
      • Bonn, Germany, 53127
        • Research Site
      • Dortmund, Germany, 44137
        • Research Site
      • Dresden, Germany, 01370
        • Research Site
      • Erlangen, Germany, 91054
        • Research Site
      • Esslingen A. N., Germany, 73730
        • Research Site
      • Frankfurt, Germany, 60488
        • Research Site
      • Hamburg, Germany, 22763
        • Research Site
      • Heidelberg, Germany, 69120
        • Research Site
      • Leipzig, Germany, 4103
        • Research Site
      • Lübeck, Germany, 23538
        • Research Site
      • München, Germany, 81377
        • Research Site
      • München, Germany, 81737
        • Research Site
      • Münster, Germany, 48129
        • Research Site
      • Tübingen, Germany, 72076
        • Research Site
      • Ulm, Germany, 89081
        • Research Site
  • Hong Kong
      • Hong Kong, Hong Kong, 999077
        • Research Site
      • Shatin, Hong Kong, 00000
        • Research Site
  • India
      • Delhi, India, 110088
        • Research Site
      • Kolkata, India, 700094
        • Research Site
      • Mumbai, India, 400012
        • Research Site
      • Mysuru, India, 570017
        • Research Site
      • New Delhi, India, 110085
        • Research Site
      • New Delhi, India, 110076
        • Research Site
      • Varanasi, India, 221005
        • Research Site
  • Italy
      • Florence, Italy, 50134
        • Research Site
      • Milan, Italy, 20162
        • Research Site
      • Milan, Italy, 20133
        • Research Site
      • Padova, Italy, 35128
        • Research Site
      • Pisa, Italy, 56126
        • Research Site
      • Rozzano, Italy, 20089
        • Research Site
      • Tricase, Lecce, Italy, 73039
        • Research Site
  • Japan
      • Hiroshima, Japan, 734-8551
        • Research Site
      • Kashiwa, Japan, 227-8577
        • Research Site
      • Kitaadachi-gun, Japan, 362-0806
        • Research Site
      • Kōtoku, Japan, 135-8550
        • Research Site
      • Mitaka-shi, Japan, 181-8611
        • Research Site
      • Nagoya, Japan, 466-8560
        • Research Site
      • Nagoya, Japan, 464-8681
        • Research Site
      • Osaka, Japan, 541-8567
        • Research Site
      • Sendai, Japan, 980-8574
        • Research Site
      • Suita-shi, Japan, 565-0871
        • Research Site
      • Toyama, Japan, 930-0194
        • Research Site
      • Ube, Japan, 755-8505
        • Research Site
      • Wakayama, Japan, 641-8510
        • Research Site
      • Yokohama, Japan, 236-0004
        • Research Site
      • Yokohama, Japan, 241-8515
        • Research Site
  • Norway
      • Oslo, Norway, 0379
        • Research Site
  • Poland
      • Bydgoszcz, Poland, 85-796
        • Research Site
      • Krakow, Poland, 31-501
        • Research Site
      • Lublin, Poland, 20-080
        • Research Site
      • Przemyśl, Poland, 37-700
        • Research Site
      • Warsaw, Poland, 02-034
        • Research Site
  • South Korea
      • Seongnam-si, South Korea, 13620
        • Research Site
      • Seoul, South Korea, 03080
        • Research Site
      • Seoul, South Korea, 03722
        • Research Site
      • Seoul, South Korea, 05505
        • Research Site
      • Seoul, South Korea, 06351
        • Research Site
      • Seoul, South Korea, 06591
        • Research Site
  • Spain
      • Barcelona, Spain, 08036
        • Research Site
      • Barcelona, Spain, 8035
        • Research Site
      • L'Hospitalet de Llobregat, Spain, 08908
        • Research Site
      • Madrid, Spain, 28041
        • Research Site
      • Madrid, Spain, 28040
        • Research Site
      • Madrid, Spain, 28007
        • Research Site
      • Málaga, Spain, 29011
        • Research Site
      • Pamplona, Spain, 31005
        • Research Site
      • Santander, Spain, 39008
        • Research Site
  • Taiwan
      • Kaohsiung City, Taiwan, 82445
        • Research Site
      • Kaohsiung City, Taiwan, 83301
        • Research Site
      • Taichung, Taiwan, 40447
        • Research Site
      • Tainan, Taiwan, 70403
        • Research Site
      • Taipei, Taiwan, 10002
        • Research Site
      • Taipei, Taiwan, 112
        • Research Site
      • Taoyuan, Taiwan, 333
        • Research Site
  • Thailand
      • Hat Yai, Thailand, 90110
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Research Site
      • Muang, Thailand, 50200
        • Research Site
      • Muang, Thailand, 34000
        • Research Site
      • Naimuang, Thailand, 30000
        • Research Site
      • Si Sa Ket, Thailand, 33000
        • Research Site
  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye), 06100
        • Research Site
      • Ankara, Turkey (Türkiye), 06230
        • Research Site
      • Antalya, Turkey (Türkiye), 07100
        • Research Site
      • Erzurum, Turkey (Türkiye), 25240
        • Research Site
      • Fatih-Istanbul, Turkey (Türkiye), 34098
        • Research Site
      • Samsun, Turkey (Türkiye), 55139
        • Research Site
  • United Kingdom
      • Cambridge, United Kingdom, CB2 0QQ
        • Research Site
      • Edgbaston, United Kingdom, B15 2WB
        • Research Site
      • Glasgow, Scotland, United Kingdom, G12 0YN
        • Research Site
      • London, United Kingdom, NW3 2QG
        • Research Site
      • Manchester, United Kingdom, M20 4BX
        • Research Site
      • Sutton, United Kingdom, SM2 5PT
        • Research Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35233
        • Research Site
    • Arizona
      • Phoenix, Arizona, United States, 85054
        • Research Site
    • California
      • Los Angeles, California, United States, 90089
        • Research Site
      • Orange, California, United States, 92868
        • Research Site
      • Stanford, California, United States, 94305
        • Research Site
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Research Site
      • Littleton, Colorado, United States, 80129
        • Research Site
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20007
        • Research Site
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Research Site
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Research Site
    • Illinois
      • Chicago, Illinois, United States, 60637
        • Research Site
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Research Site
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Research Site
    • Kentucky
      • Lexington, Kentucky, United States, 40506
        • Research Site
    • Louisiana
      • New Orleans, Louisiana, United States, 70121
        • Research Site
    • Michigan
      • Grand Rapids, Michigan, United States, 49503
        • Research Site
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Research Site
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Research Site
    • New York
      • Commack, New York, United States, 11725
        • Research Site
      • Mineola, New York, United States, 11501
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19144
        • Research Site
    • Texas
      • Dallas, Texas, United States, 75246
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1)
  • Provision of a tumor sample collected at surgical resection.
  • Randomization within 12 weeks after resection with adequate healing and removal of drains.
  • Confirmed to be disease-free by imaging within 28 days prior to randomization.
  • Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion Criteria:

  • Participants with locally-advanced, unresectable, or metastatic disease at initial diagnosis.
  • Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine neoplasms and nonepithelial tumors.
  • Any anti-cancer therapy for BTC prior to surgery
  • Active or prior documented autoimmune or inflammatory disorders or any severe or uncontrolled systemic disease
  • Current or prior use of immunosuppressive medication within 14 days before the first dose
  • Thromboembolic event within 3 months
  • Active HBV or HCV infection unless treated.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Arm A
Rilvegostomig IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)
Drug: Rilvegostomig
Rilvegostomig IV (intravenous) Q3W
Drug: Capecitabine
Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Drug: Gemcitabine/Cisplatin
Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
Drug: S-1 [Tegafur/Oteracil/gimeracil]
S-1 [Tegafur/Oteracil/gimeracil] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
Placebo Comparator: Arm B
Placebo IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)
Drug: Capecitabine
Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Drug: Gemcitabine/Cisplatin
Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
Drug: S-1 [Tegafur/Oteracil/gimeracil]
S-1 [Tegafur/Oteracil/gimeracil] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
Drug: Placebo
Placebo IV (intravenous) Q3W

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Recurrence free survival (RFS) for Arm A vs. Arm B
Time Frame: Approximately 5 years
Recurrence-free survival (RFS) is defined as the time from randomization until the date of radiological recurrence guided by RECIST 1.1 or death due to any cause, whichever occurs first.
Approximately 5 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Overall Survival (OS) for Arm A vs. Arm B
Time Frame: up to 7 years
Overall survival is defined as the time from randomization until the date of death due to any cause.
up to 7 years

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Patient-reported tolerability Arm A vs. Arm B.
Time Frame: Up to approximately 7 years.
Patient-reported tolerability is a multi-component endpoint defined as the proportion of participants in each arm reporting side effect bother, clinically meaningful impact on physical functioning and descriptive data on treatment-related symptoms.
Up to approximately 7 years.
Progression Free Survival (PFS) following recurrence Arm A vs. Arm B.
Time Frame: Up to approximately 7years
Progression-free survival following recurrence is defined as the time from randomization until the earliest progression event after the start of the first subsequent therapy or death.
Up to approximately 7years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
AstraZeneca

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 4, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 2, 2029

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 3, 2030

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 26, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 26, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 31, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • D7025C00001
  • 2023-506054-20-00 (Other Identifier: EU Clinical Trial Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD Sharing Access Criteria

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings